BioNetwork West 2015 (past event)

October 26 - 28, 2015

Contact Us: 1.888.482.6012

Kia Motesharei, Head, Global Licensing & Business Development, Immunology at EMD Serono / Merck KGaA
EMD Serono / Merck KGaA Logo

Kia Motesharei


Head, Global Licensing & Business Development, Immunology
EMD Serono / Merck KGaA

Check out the incredible speaker line-up to see who will be joining Kia.

Download The Latest Agenda

Innovative Dealmaking

Friday, February 10th, 2017


09:00 Therapeutic Focus Area Ice Breaker Roundtables

Get to know others with similar interests as you. Choose the therapeutic area at the top of your partnership priorities. You'll sit with 10 - 20 others seeking similar opportunities to debate the advantages and challenges assocatied with your chosen area, and start making connections!

#1 Neurodegenerative Diseases
Ilan Zipkin, Senior Investment Director, Takeda Ventures

#2 Rare Disease
Joshua A. Grass, SVP, Business and Corporate Development, BioMarin Pharmaceutical

#3 Biosimilars Across Therapeutic Areas
Michael Bayewitch, Director, Search & Evaluation, Biologics, Teva Pharmaceuticals

#4 Immunology
Kia Motesharei, Head, Global Licensing & Business Development, Immunology, EMD Serono

#5 Gene Therapy
John McDonald, VP Business Development and Mergers & Acquisitions, Biogen

#6 Oncology
Michael Attar, Executive Director, Business Development, Celgene Corporation

#7 Other (Free Flow Table)

11:10 PANEL: Enhancing The Deal And Minimizing Complications Through Improved Due Diligence And Insight Generation

• Identifying steps for effective due diligence from early stage asset valuation to the late stages of the deal
• Using external insights and experts to know as much as you can about an asset and its potential before the late stages of the deal
• How can you start the due diligence process earlier to strengthen the relationship and problem solve?
• Lining up the many moving pieces in tight timelines to build trust
• Success stories of effective due diligence across the entire business development and licensing spectrum